Abstract
Objective
To investigate the safety and feasibility of laparoendoscopic single-site surgery (LESS) in the treatment of giant ovarian cysts.
Methods
A total of 76 patients with giant ovarian cyst (diameter ≥ 10 cm) who received surgical treatment in our hospital from January 2018 to May 2021 were divided into experimental cohort (single-port laparoscopic cohort) (n = 30) and control cohort (traditional laparoscopic cohort) (n = 46).The operation time, intraoperative blood loss, intraoperative cyst fluid spillage rate, application of postoperative analgesic drugs, postoperative first anus exhaust time, incidence rate of perioperative complications, length of postoperative hospital stay and other clinical indicators were summarized and analyzed between the two cohorts.
Results
The LESS cohorts had an earlier onset of age[ (27.6 ± 8.4) ,years of age], shorter of operation time [(82.2 ± 16.0)min], less of intraoperative blood loss [( 17.5 (10-22.5) ml)] as compared with traditional laparoscopic cohort[ (40.9 ± 15.5 )years of age, (102.7 ± 26.2)min, (20 (18.7–35) )m,P ༜ 0.05]. The first postoperative exhaust time,the rate of postoperative analgesic drugs, incidence rate of perioperative complications and postoperative hospital stay in two cohorts were in the similar line.
Conclusion
After adequate evaluation and screening of patients, the size of ovarian cysts cannot be the reason for refusing LESS surgery. It is safe and feasible for clinical promotion in the management of giant ovarian cysts.